Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2017-04-26 Earnings Release
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Biotest recalls human albumin and reduces forecast
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc RELEASE' dated April 26, 2017, disclosing 'inside information acc. to Article 17 MAR' (European Market Abuse Regulation). It announces a product recall and a reduction in the EBIT and sales guidance (a profit warning). This type of immediate, material, non-scheduled disclosure of price-sensitive information, especially concerning financial outlook adjustments, is typically classified as a Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it were a scheduled result announcement. Since it is an unscheduled, mandatory disclosure of material non-public information (MNPI) under MAR, and it is not a full report (10-K, IR), a specific management discussion (MDA), or a formal earnings release (ER) but rather an immediate regulatory alert, the most appropriate general category for mandatory, unscheduled regulatory disclosures that don't fit elsewhere is RNS. However, given the content is explicitly a reduction in financial guidance (a profit warning), it strongly relates to financial performance updates. Since 'ER' is defined as the 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is an unscheduled announcement of revised guidance, RNS is the best fit as a general regulatory disclosure mechanism under MAR, or potentially a very specific type of ER/Profit Warning not explicitly listed. Given the options, RNS (Regulatory Filings) serves as the best catch-all for mandatory MAR disclosures that aren't standard reports or specific management discussions. The document length is short (4316 chars) and it is a direct announcement, not an attachment, ruling out RPA based on the 'MENU VS MEAL' rule if it were announcing a larger document. It is the announcement itself. FY 2017
2017-04-26 English
Biotest AG: Biotest AG opens sixth plasma collection centre in Hungary
Regulatory Filings Classification · 100% confidence The document is a short press release dated April 19, 2017, announcing that Biotest AG opened a new plasma collection center in Hungary. It contains general corporate news, contact information, and a disclaimer, but it does not appear to be a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement disseminated via DGAP. Since it doesn't fit into specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), and it is not a presentation (IP) or a transcript (CT), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous news releases that don't fit elsewhere.
2017-04-19 English
Biotest AG: Biotest informs about limited availability of albumin
Legal Proceedings Report Classification · 99% confidence The document is a short press release dated April 13, 2017, announcing a supply shortage of albumin due to equipment failure and stating that the consequences on sales and annual results are currently not assessable. It is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal dividend/share change notice. It is an announcement concerning operational issues that will impact future financial results. Since it is a general corporate news item disseminated via DGAP (a service often used for regulatory news), and it doesn't fit the specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements not covered elsewhere, especially when they are brief news items.
2017-04-13 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections detailing the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in voting rights percentages (e.g., crossing thresholds from 4.03% to 5.21%) held by a specific entity (J O Hambro Capital Management Ltd) in the issuer (Biotest AG). This directly corresponds to the definition of a Major Shareholding Notification.
2017-04-13 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is explicitly titled 'Notification of Major Holdings' and details the acquisition/disposal of shares with voting rights by J O Hambro Capital Management Ltd, crossing a threshold on 10 Apr 2017. It reports specific percentages of voting rights (4.03% direct, 0.04% indirect) and the total number of voting rights. This content directly corresponds to regulatory filings concerning changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). Although it is distributed via DGAP (a regulatory service), the core content is the holding notification itself, not just an announcement of a report (RPA/RNS).
2017-04-11 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly contains the header "Voting Rights Announcements" and discusses the retraction of a previous notification regarding the crossing of notification thresholds, which directly relates to changes in significant share ownership or voting rights. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions DGAP distribution, the core content is a voting rights update, not just a general announcement of a report release (RPA/RNS).
2017-04-11 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.